Skip to main content
Log in

Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study

  • Clinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer. Eight patients had received no prior systemic therapy for their metastatic disease and 13 had only one site of metastasis. Toxicity occurred in 18 of the 33 patients and was primarily gastrointestinal. It ranged in severity from mild to severe with 4 patients discontinuing treatment early because of nausea, vomiting, diarrhea or stomatitis. One response, of 8 weeks duration, was noted in 29 evaluable patients. We conclude that flutamide does not have meaningful anti-tumour activity in breast cancer and plan no further trials of the drug in this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. De Vita Jr VT: Cancer: Principles and Practice of Oncology, 2nd ed., pp 1150–1155, J.B. Lippincott Co., Philadelphia

  2. Lippman ME, Allegra JC: Current concepts in cancer — receptors in breast cancer. N Eng J Med 299:930–933, 1987

    Google Scholar 

  3. Osborne CK, Yochmowitz MG, Night WA, McGuire WL: Steroid receptors in breast cancer. Cancer 46:2884–2888, 1980

    Google Scholar 

  4. Miller WR, Telford J, Dixon JM, Hawkins RA: Androgen receptor activity in human breast cancer and its relationship with estrogen and progestogen receptor activity. Eur J Cancer Clin Oncol 21(4):539–542, 1985

    Google Scholar 

  5. Teulings FAG, van Gilse HA, Henkelman MS, Portengen H, Alexieva-Figusch J: Estrogen, androgen, glucocorticoid and progesterone receptors in progestin-induced regression of human breast cancer. Cancer Res 40:2557–2561, 1980

    Google Scholar 

  6. Cowan K, Lippman M: Steroid receptors in breast cancer. Arch Intern Med 142:363–366, 1982

    Google Scholar 

  7. Poortman J, Prenen JAC, Schwarz F, Thijssen JHH: Interaction of delta-5-androstene-3-beta, 17 beta-diol with estradiol and dihydrotestosterone receptors in human myometrial and mammary cancer tissue. J Clin Endocrinol Metab 40(3):373–379, 1975

    Google Scholar 

  8. Adams J: Steroid hormones and human breast cancer — an hypothesis. Cancer 40:325–333, 1977

    Google Scholar 

  9. Neumann F, Jacobi GH: Anti-androgens in tumor therapy. Clinics in Oncology 1(1):41–64, 1982

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perrault, D.J., Logan, D.M., Stewart, D.J. et al. Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs 6, 207–210 (1988). https://doi.org/10.1007/BF00175399

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00175399

Key words

Navigation